Levothyroxine treatment in women with thyroid antibodies may not increase live birth rate
Treating women with thyroid antibodies but a normal thyroid function with a medicine called Levothyroxine does not make them more likely to deliver a live baby, new research led by the University of Birmingham suggests.
The research, which was led by researchers from the Institute of Metabolism and Systems Research, Birmingham Clinical Trials Unit, the Institute of Applied Health Research, and Tommy’s Centre for Miscarriage Research at the University of Birmingham, was published today in New England Journal of Medicine. Funded by the MRC and the National Institute for Health Research (NIHR), the research was also presented today at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, USA.
Miscarriage occurs in one in five women who conceive, making it one of the most common complications of pregnancy. Previous research has found a strong association between the presence of thyroid peroxidase antibodies and miscarriage. However, it was unclear from previous evidence whether treating women with normal thyroid function and with thyroid peroxidase antibodies with Levothyroxine would improve live-birth rates.
The University of Birmingham has now led the largest study of its kind to investigate whether treatment with Levothyroxine would increase the rates of live births at or beyond 34 weeks gestation among women who have thyroid antibodies and also a history of miscarriage or reduced fertility.
Lead author Dr Rima Dhillon-Smith, an academic clinical lecturer at the University of Birmingham, said: "Our research has found that Levothyroxine treatment, started before pregnancy, in women with normal thyroid function and thyroid peroxidase antibodies who have a history of miscarriage or infertility, does not improve the chances of live birth.
"We were surprised by the results of our study as previous small studies suggested there could be a benefit of Levothyroxine treatment in women with thyroid antibodies.”
The authors conducted a study of 940 women at 49 UK hospitals with normal thyroid function aged between 16 and 41 who were positive for thyroid peroxidase antibodies; had a history of miscarriage or infertility, and were trying to conceive naturally or with assisted conception.
The study, carried out between 2011 and 2017, saw 470 women receive 50mcg daily of Levothyroxine and 470 women receive a daily placebo. The participants began taking the medication before they conceived and continued until the end of their pregnancy.
Outcomes in both groups were similar: 266 of the 470 (56.6 per cent) women who received Levothyroxine, and 274 of 470 (58.3 per cent) women who received a placebo, became pregnant; 176 women (37.4 per cent) taking Levothyroxine, and 178 (37.9 per cent) taking a placebo, had live births.
Dr Rima Dhillon-Smith added: "Thyroid peroxidase antibodies are found in the blood in approximately one in 10 women who have normal thyroid function, and they have been linked to increased risk of miscarriage and preterm birth.
"International guidelines currently recommend the consideration of Levothyroxine treatment for women with thyroid antibodies, as there is thought to be minimal chance of harm and a potential to help increase the chance of having a live birth.
"As our study was large and of high quality, we can now be confident that Levothyroxine does not improve pregnancy success for women with thyroid antibodies and normal thyroid function and therefore should not be recommended or used in clinical practice. This will mean no longer providing unnecessary medication to women who do not need it."
Dr Kristien Boelaert, also of the University of Birmingham, said: “Our trial has definitively answered an important clinical question.
“In a recent survey we carried out of UK fertility clinicians almost 40 per cent said they routinely use Levothyroxine in women with thyroid peroxidase antibodies to reduce miscarriage and pre-term birth.
“We now pose the question of whether testing for thyroid peroxidase antibodies should be performed at all in women with infertility or previous miscarriages.
“While thyroid peroxidase antibodies testing may inform about future risk of progression to thyroid disease, our research has shown its treatment with Levothyroxine does not improve pregnancy outcomes and may only generate patient anxiety and unnecessary healthcare costs.
“We hope that national and international guidelines are updated to remove current recommendations which advise consideration of the use of Levothyroxine in these women.
“We also hope that the current practice of routine testing of thyroid peroxidase antibodies in high risk populations such as women with miscarriage and reduced fertility is re-considered.”
For more information contact Emma McKinney, Communications Manager (Health Sciences), University of Birmingham, tel: +44 (0) 121 414 6681, or contact the press office out of hours on +44 (0) 7789 921 165.
Notes to Editors
- The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 6,500 international students from over 150 countries.
- Dhillon-Smith et al (2019). 'Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. New England Journal of Medicine.'
- The research was carried out in collaboration with Birmingham Women’s and Children’s Foundation Trust, the University of Oxford, The Miscarriage Association, University Hospitals Coventry & Warwickshire NHS Trust, East Lancashire Hospitals NHS Trust, Central Manchester University Hospital Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, University College Hospitals NHS Foundation Trust, Guy’s and St Thomas’ NHS Foundation Trust, University Hospital of Crosshouse, Bolton NHS Foundation Trust, Chelsea and Westminster NHS Foundation Trust, University Hospitals Bristol NHS Foundation Trust, Imperial College Healthcare NHS Trust, Nottingham University Hospitals NHS Trust, King’s College Hospital NHS Foundation Trust, The Shrewsbury and Telford NHS Trust, Queen Mary University of London, and the University of Nottingham.
- The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
- The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
- The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR commissions applied health research to benefit the poorest people in low- and middle-income countries, using Official Development Assistance funding.